Opinion|Videos|June 19, 2024
PDTs' Role in Addressing Health Care Disparities and Priorities for Improving PDT Access
In their closing remarks, the panel shares their view on the future of prescription digital therapeutics and the prospects for the widespread adoption and implementation of these therapeutics in health care systems.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- How can payers work with providers to establish protocols for appropriate PDT prescribing and monitoring efficacy?
- What opportunities exist for collaborative demonstration projects across payers, providers, manufacturers, and other stakeholders to generate evidence on optimal implementation strategies?
- How might PDTs potentially help mitigate or reduce healthcare disparities and inequities in access to treatment or health outcomes across different populations?
- How important is it that Congress pass the Access to Prescription Digital Therapeutics Actas you consider the long-term value PDTs can have on improving care to patients?
Advertisement
Related to this article
Phase 3 Viti-Up trials show Rinvoq (upadacitinib) JAK inhibitor boosts facial and body repigmentation in nonsegmental vitiligo, with familiar safety.
Machine learning prediction of procalcitonin positivity using inexpensive routine laboratory tests may reduce procalcitonin test volume and support diagnostic stewardship.
A population-based study of 1102 Canadian children found infants with bone and soft tissue tumors had poorer survival, driven largely by treatment deaths.
After Pennsylvania began rewarding Medicaid managed care plans for increasing well-child visits among Black infants, rates did not change significantly overall but varied by region.
Liver disease disparities tied to insurance and race spanned HCC surveillance, transplant listing, and drug access in data at The Liver Meeting 2026.
A case report describes the first KRAS::ETNK1 fusion in MDS/MPN with eosinophilia; the fusion disappeared when disease relapsed as AML after transplant.
Hepatitis B functional cure with bepirovirsen held in 90% to 92% of responders 48 weeks after stopping all therapy, per data at The Liver Meeting 2026.
GOLD leaders say COPD is diagnosed too late and its smoking-only image is outdated, and the 2027 report puts rehab and non–drug care up front.
Advertisement
Advertisement
Trending on AJMC
1
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
2
Health Equity & Access Weekly Roundup: November 6, 2026
3
Medicaid Cuts and Caregiving in Congress: Andy Kim
4
COPD’s Old Narrative Is Outdated, GOLD Leaders Say in 2027 Update
5